Update on HPV Vaccination

Abstract

Human papillomavirus is a sexually transmitted virus responsible for cancer of the cervix, vagina, vulva, anus, penis, oral cavity, and oropharynx. Primary prevention of this infection by HPV vaccination can prevent most cases of cervical cancer in women, if given before sexual debut. Though the quadrivalent and bivalent vaccines were approved by the FDA in 2006 and 2009, respectively, the 9-valent vaccine was approved in 2017. This chapter will discuss the newly available nonavalent HPV vaccine (its rationale, efficacy, and cost-effectiveness comparable to older vaccines), changes in dosage schedules, safety updates, and under research therapeutic vaccines.

Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10:845.CrossRefGoogle Scholar